Myriad Genetics (MYGN -2.3%) slips today, despite reaffirming its FY13 outlook. The company says it's anticipating its EPS at the higher end of its guidance range of $1.55 - $1.58, in line with the Street consensus of $1.58. It also maintains FY13 revenue at the higher end of its $575M - $585M range as well. Analysts are looking for $583.3M. However, Oppenheimimer cut its price target on the shares after Noridian, the Medicare contractor for Utah, reduced Integrated BRACAnalysis pricing by 16.3%. MYGN gets 10% of its revenue from Medicare.